Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Mirum Pharmaceuticals, Inc.
A pharmaceutical company focused on rare diseases, it markets three FDA-approved medicines: Livmarli for the severe itching of certain inherited liver conditions, Ctexli for cerebrotendinous xanthomatosis, and Cholbam for bile acid disorders. It was founded in 2018 by a team that revived its lead drug after pharmaceutical giant Shire set it aside, and its name comes from Latin, meaning "wonder" or "marvel."
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events
8.01 Other Events
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits